University of Birmingham's cancer immunotherapy developer Revitope Oncology secured equity funding as part of a $160m alliance with Junshi Biosciences.

Revitope Oncology, a US-based cancer therapeutics spinout of University of Birmingham, is set to receive $10m in equity funding from biopharmaceutical firm Junshi Biosciences as part of a collaboration and licensing agreement. Junshi could supply as much as $160m for each molecule discovered under the partnership in milestones and royalties.  The equity funding is in…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.